US Doctors Issue First Menopause Treatment Update in 12 Years as Hormone Therapy Returns to First-Line Care

America’s leading obstetricians and gynaecologists have issued their first major update to menopause care in twelve years, restoring hormone therapy to its place as the first-line treatment for the hot flashes, night sweats and broken sleep that affect more than half of women going through the menopause. The new guidance, published by the American College of Obstetricians and Gynecologists (ACOG), marks the most decisive break yet with two decades of caution that followed a landmark study in 2002, and it arrives months after the US Food and Drug Administration (FDA) stripped the sternest safety warnings from hormone therapy labels.

ACOG’s Clinical Practice Guideline No. 13, titled Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms, was published on 15 October 2026 in the journal Obstetrics & Gynecology and replaces guidance dating from 2014, according to ACOG. The organisation describes it as its most comprehensive menopause guidance to date. The recommendations were reported by the Associated Press on 31 October 2026 and covered by ABC News, drawing on interviews with the college’s president and with independent specialists in women’s health.

At the heart of the guidance is a clear, strongly worded recommendation: systemic menopausal hormone therapy should be the first treatment offered for moderate to severe hot flashes and night sweats, and for the sleep problems those symptoms cause, in women who have no medical reason to avoid hormones. Women who still have a uterus should receive oestrogen combined with a progestogen, which protects the lining of the womb; women who do not need that protection may receive oestrogen alone, according to ACOG.

The guidance is equally specific about timing. When a woman chooses hormone therapy, ACOG strongly recommends starting it before the age of 60, or within ten years of the onset of natural menopause. That window, the college says, is where the balance of benefit and risk is most favourable. Decisions should be made jointly by the patient and her doctor, taking into account age, medical history, cardiovascular risk, breast cancer risk and the risk of blood clots.

“We would love our patients to go to their OB-GYNs regarding questions about menopause and really advocate for getting the treatment that they need,” Dr Camille Clare, ACOG’s president, told the Associated Press. More than half of women in menopause report vasomotor symptoms such as hot flashes and night sweats, ACOG says, and up to two-thirds face disruption to their sleep.

The update also gives detailed attention to women who cannot take hormones, or who prefer not to. For them, ACOG strongly recommends a newer class of non-hormonal medicines called neurokinin receptor antagonists, which includes fezolinetant, sold as Veozah, and elinzanetant, sold as Lynkuet. The college also recommends antidepressant medicines known as SSRIs and SNRIs, which can help with hot flashes, and it endorses non-drug approaches including cognitive behavioural therapy, mindfulness-based interventions, physical exercise and clinical hypnosis. Acupuncture is also mentioned among the options with supporting evidence.

Just as notable is what the guidance rules out. ACOG says the evidence does not support soy isoflavones, other plant oestrogens or herbal supplements for menopause symptoms, and it does not support progestogen alone, the hormone DHEA or testosterone for these symptoms. On mood, the picture is less settled: the college found the evidence insufficient to recommend for or against hormone therapy specifically for menopause-related depressive symptoms.

What the new guidance recommends

The guideline divides menopause symptoms into three groups — vasomotor symptoms, sleep and mood — and deals with each in turn. Vasomotor symptoms are the hot flashes and night sweats that are the most recognisable feature of the menopause. They are caused by the narrowing of the body’s temperature-control range as oestrogen levels fall, and they can last for years. ACOG’s central finding is that systemic hormone therapy is the most effective treatment for them, a conclusion that specialists outside the college have echoed.

“Moderate to severe or bothersome menopausal symptoms should be treated with hormone therapy as the first line of treatment,” Dr JoAnn Manson, a professor of medicine at Harvard Medical School, told the Associated Press. Dr Manson added that ACOG’s new guidelines are similar to those issued by other medical organisations. Dr Stephanie Faubion, medical director at The Menopause Society, said she was glad to see the emphasis on hormone therapy. “It’s undisputed that hormone therapy is the first line and most effective therapy for hot flashes,” she said.

The guidance also distinguishes between whole-body and local treatments. Systemic therapies, which come as pills, patches, sprays, gels and a vaginal ring, deliver hormones into the bloodstream at levels high enough to affect symptoms such as hot flashes. Low-dose vaginal oestrogen, applied directly where it is needed, delivers very little hormone into the bloodstream and is used for local symptoms rather than hot flashes.

For sleep, the guidance takes a two-track approach. Because much menopause-related sleep disruption is caused by night sweats waking women repeatedly, treating the hot flashes themselves often restores sleep. ACOG therefore strongly recommends systemic hormone therapy for sleep problems caused by vasomotor symptoms, and it conditionally suggests a combination of conjugated oestrogen and bazedoxifene as an alternative for the same problem. For women who cannot use hormones, the neurokinin drugs fezolinetant and elinzanetant are strongly recommended for hot flashes and the sleep problems that accompany them.

The non-drug options are given real weight rather than being listed as an afterthought. ACOG recommends cognitive behavioural therapy to help with hot flashes, sleep disturbances and mood symptoms, and it says mindfulness-based interventions and physical exercise may help improve sleep and mood, while clinical hypnosis may reduce hot flashes and improve sleep and anxiety symptoms. These are the options most likely to matter for women who have had breast cancer, blood clots or other conditions that rule out hormones.

The shadow of 2002: how fear shaped two decades of care

To understand why a routine clinical update has drawn so much attention, it is necessary to go back to 2002. That year, a landmark study called the Women’s Health Initiative was stopped early after researchers found links between a pill-based combination of oestrogen and progestin and breast cancer, blood clots and other serious problems. The findings were reported around the world, hormone therapy use collapsed, and millions of women stopped treatment.

For more than 22 years afterwards, all hormone-based menopause treatments carried a boxed warning — the US government’s most serious safety label — flagging risks of cardiovascular disease, breast cancer and probable dementia. The warning, in place since 2003, discouraged patients and doctors from using the treatments even as later research suggested the original study’s risks had been overstated for younger women starting treatment near the menopause.

The turning point came in stages. In November 2025, the FDA announced it would remove the boxed warning statements on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, following a comprehensive review of the science and an expert panel convened in July 2025. On 12 February 2026, the agency approved labelling changes for the first six products, covering combination oestrogen-progestogen therapy, oestrogen-alone therapy, progestogen-alone therapy and topical vaginal oestrogen.

The FDA was careful to say what had not changed. The boxed warning about endometrial cancer remains on systemic oestrogen-alone products for women who still have a uterus, and the other risks are still listed in the warnings and precautions sections of the labels. Announcing the change, Health and Human Services Secretary Robert F. Kennedy Jr. said the decision reflected “our commitment to follow the science wherever it leads,” while FDA Commissioner Marty Makary said the update was about giving women and their doctors accurate, age-specific information. The agency’s review found that randomised studies show women who start hormone therapy within ten years of menopause onset, generally before age 60, have reduced all-cause mortality and fewer fractures.

ACOG’s guideline is the clinical profession’s answer to that regulatory shift. Where the FDA changed what the label says, ACOG has now changed what doctors are told to do. The two moves together complete a reversal that began more than twenty years ago and that, in the college’s judgement, is now supported by the weight of the evidence.

Why the timing window matters

The most important practical point in the new guidance is also the easiest to misunderstand: when treatment starts matters as much as whether it starts at all. ACOG strongly recommends beginning hormone therapy before age 60 or within ten years of the onset of natural menopause, because the benefits at that point appear to outweigh the risks. The same treatment started much later carries a different balance.

This is the idea researchers call the timing hypothesis. In the years immediately after the menopause, oestrogen appears to protect blood vessels and bones; a decade or more later, when arteries have already stiffened and disease is established, the same hormone may do more harm than good. The Women’s Health Initiative, whose average participant was 63 years old and more than a decade past the menopause, tested hormone therapy largely in the wrong group for the question most women were asking, which was whether treatment was safe for a healthy 51-year-old with severe hot flashes.

The FDA’s review, published in the Journal of the American Medical Association in 2026, found that women who begin therapy within ten years of menopause onset, particularly before age 60, saw a reduction in all-cause mortality and in fractures. The Menopause Society’s 2022 position statement reached a similar conclusion, stating that for most healthy, symptomatic women under 60 or within ten years of menopause onset, the benefits of hormone therapy outweigh the risks.

For women reading the new guidance, the implication is practical. A woman of 52 with drenching night sweats and a healthy heart is in a very different position from a woman of 72 with established heart disease who has never taken hormones, and the guidance is written to reflect that difference. Age, time since menopause, personal and family history of breast cancer, and clotting risk all feed into the shared decision the guideline describes.

Beyond hormones: the non-drug options

One of the most striking features of the new guidance is how seriously it treats treatments that involve no medicine at all. Cognitive behavioural therapy, which helps women reframe their response to hot flashes and the anxiety that surrounds them, is recommended for hot flashes, sleep disturbances and mood symptoms. Mindfulness-based interventions and regular physical exercise are endorsed for sleep and mood, and clinical hypnosis is noted as an option that may reduce hot flashes and improve sleep and anxiety.

These recommendations matter for two reasons. First, a substantial minority of women cannot take hormones: those with a history of breast cancer, blood clots, stroke or certain liver conditions, and those taking medicines that interact with oestrogen. For them, the non-hormonal drugs and the behavioural approaches are not second-best consolations but the main treatment, and the guidance now describes them with the same rigour it applies to hormones. Second, many women who could take hormones prefer not to, and the guideline’s structure allows a doctor to build a treatment plan around that preference without implying the woman is settling for less.

The new non-hormonal drugs deserve particular attention. Fezolinetant and elinzanetant work by blocking neurokinin receptors in the brain’s temperature-control centre, the mechanism that triggers a hot flash. They were developed precisely because so many women were left without an effective option after the 2002 scare, and specialists quoted in medical coverage of the guideline have described them as a game-changer for women who cannot take hormones. Their inclusion as a strong recommendation, rather than a footnote, signals how far menopause care has moved from a single-drug model.

By contrast, the guidance is blunt about products that do not work. Soy isoflavones, other plant oestrogens and herbal supplements — a large and heavily marketed category — are not supported by the evidence for menopause symptoms, according to ACOG. The same applies to progestogen alone, DHEA and testosterone when used for hot flashes, sleep and mood. In a field crowded with commercial claims, that clarity is itself a form of care.

What the guidance does not cover

The guideline is deliberately narrow in scope. It covers vasomotor symptoms, sleep and mood. It does not address genitourinary syndrome of menopause — the vaginal dryness, irritation and urinary symptoms that affect quality of life as much as hot flashes do for many women. ACOG is developing separate guidance on that topic, expected in 2027, and the omission is a reminder that this update is a step in a longer process rather than the last word.

The evidence on mood is also left open. ACOG found the evidence insufficient to recommend for or against hormone therapy specifically for menopause-related depressive symptoms, a careful formulation that reflects how difficult it is to separate the direct effects of falling oestrogen on mood from the indirect effects of months of broken sleep. Women whose low mood is driven by exhaustion may feel better once their sleep is restored; women with clinical depression need treatment in its own right.

Separately, The Menopause Society used its 2026 annual meeting in San Diego to release updated clinical guidance urging doctors to screen for menopause earlier. Physicians often miss the diagnosis when patients report fatigue, brain fog or joint pain rather than classic hot flashes, and the new recommendations urge screening for menopause in any patient aged 40 or younger who reports non-specific symptoms, using standardised rating scales or prompts in electronic health records. The two sets of guidance, taken together, address both ends of the problem: recognising menopause earlier and treating it better once it is recognised.

There is also a practical obstacle the guidance cannot solve on its own. Some women have reported difficulties obtaining specific hormone formulations, and federal officials said on Friday that the FDA has been taking steps to ensure there is an adequate supply. A recommendation is only as good as the pharmacy shelf, and shortages of particular patches, gels or doses have frustrated patients and clinicians alike in recent years.

Analysis: Why It Matters

A correction, not a fashion

It is tempting to describe this guidance as a swing of the pendulum, from enthusiasm for hormone therapy in the 1990s to fear in the 2000s and back to enthusiasm now. That would be the wrong frame. What has changed is not fashion but evidence, accumulated over twenty years of follow-up studies, re-analyses and new trials. The 2002 findings were real, but they described a specific population — older women, many years past the menopause, taking a specific oral combination — and they were generalised far beyond what the data supported. The correction now being made is not a return to uncritical prescribing; it is the replacement of a blanket warning with a precise, age-specific assessment of who benefits and who does not. That is how medicine is supposed to work, and the fact that it took more than two decades is a measure of how hard it is to undo a frightening headline.

The trust deficit is the real disease

The deeper problem the guidance must overcome is not scientific but human: trust. A generation of women were told, in the starkest possible terms, that hormone therapy might give them breast cancer or a stroke. Many stopped treatment overnight and never resumed it. Many more, reaching the menopause in the years since, never asked for it at all. Doctors, fearful of liability and uncertain of the evidence, stopped offering it. The result is a vast untreated burden — millions of women enduring years of broken sleep, lost productivity and diminished quality of life for want of a treatment that, for most of them, was safer than they were led to believe. ACOG’s president urging women to “advocate for getting the treatment that they need” is an acknowledgement that the guidance must fight not only ignorance but memory. Rebuilding that trust will take more than one guideline; it will take doctors willing to raise the subject, patients willing to ask, and honest conversations about risk that neither minimise nor exaggerate.

Access will decide whether the guidance matters

Guidelines do not treat patients; clinics, pharmacies and health systems do. The new recommendations will mean little if women cannot find a clinician trained in menopause care, if appointments are too short for the shared decision-making the guideline prescribes, or if the specific formulation prescribed is out of stock. The supply difficulties some women have already reported are an early warning. There is also a geography problem: menopause expertise is concentrated in specialist clinics and urban centres, while the women who need it live everywhere. If the guidance is to change outcomes rather than merely opinions, it will need to be followed by training for primary care doctors, who see most menopausal women, and by attention to the supply chain for the products it recommends. The history of this field suggests that the gap between what the evidence says and what patients receive is where good intentions go to die.

Menopause care is becoming whole-person care

Look at the full shape of the guidance and a broader shift comes into view. The document does not merely rank drugs; it treats sleep, mood, exercise, psychological therapy and hypnosis as legitimate parts of menopause care, and it pairs that with earlier screening guidance from The Menopause Society that treats fatigue and brain fog as symptoms worth investigating rather than complaints to be dismissed. This is a move away from the model in which menopause was a hormone deficiency to be corrected and towards one in which it is a life stage to be managed in the round — with medicines where they help, behavioural tools where they help, and attention to work, relationships and daily functioning. That shift matters because it matches how women actually experience the menopause: not as a single symptom but as a cluster of disruptions to sleep, work, mood and confidence. The workplace dimension is real and under-discussed; symptoms frequently arrive in women’s peak career years, bringing brain fog and anxiety to the very moment they are earning leadership roles, and surveys have found many women feel pressure to hide their symptoms at work. Guidance that takes sleep and mood seriously is guidance that takes women’s working lives seriously.

A test for how medicine handles uncertainty

Finally, this episode is a test case for a question that extends far beyond menopause: how should medicine correct itself when it gets something wrong? The honest answer is slowly, publicly and with evidence — which is what has happened here, through the FDA’s labelling review, the JAMA analysis and now ACOG’s guideline. But the process has also revealed the asymmetry at the heart of medical communication: a frightening result travels instantly and lodges permanently, while a careful correction travels slowly and is received sceptically. If the profession wants the correction to land, it will need to communicate with the same clarity and urgency it once brought to the warning, and to accept that some women, having weighed the evidence, will still choose not to take hormones — a choice the guidance itself respects. The measure of success is not how many women start hormone therapy; it is how many women make an informed choice, with a clinician who knows the evidence and a system that can deliver what they choose.

What to Watch Next

1. Uptake in primary care: whether family doctors and general practitioners, who see most menopausal women, adopt the new recommendations — or whether prescribing remains concentrated in specialist menopause clinics.
2. Supply of hormone products: whether the FDA’s steps to ensure adequate supply resolve the shortages of specific patches, gels and doses that some women have reported, and whether new generic products ease access.
3. The 2027 genitourinary guidance: ACOG’s promised separate guidance on vaginal and urinary symptoms, which the current document deliberately leaves out, will complete the picture for many women.
4. Long-term data on the new non-hormonal drugs: fezolinetant and elinzanetant are recent arrivals; real-world safety and effectiveness data over the coming years will determine how widely they are used.
5. Earlier diagnosis: whether The Menopause Society’s push to screen women aged 40 and under with non-specific symptoms such as fatigue and brain fog shortens the years many women currently spend without a diagnosis.

This article reports on published clinical guidance and is not medical advice. Decisions about hormone therapy should be made with a qualified clinician, taking into account individual medical history and risk factors.

Sources

• Associated Press — “There’s new guidance on menopause symptoms like hot flashes. What women need to know” (31 October 2026)
• American College of Obstetricians and Gynecologists — “Better Menopause Care Begins With Asking” (summary of Clinical Practice Guideline No. 13)
• US Food and Drug Administration — “FDA approves labeling changes to menopausal hormone therapy products” (12 February 2026)
• HealthDay via MedicineNet — “A Doctor’s Take On New Menopause Guidelines” (27 October 2026)
• Health and Me — “Hot Flashes To Night Sweats: Leading US OB-GYN Group Updates Menopause Treatment Guidance After 12 Years”